- Home
- ISPR vs PACB Comparison
ISPR vs PACB Comparison
Compare ISPR & PACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ISPR
- PACB
- Stock Information
- Founded
- ISPR 2019
- PACB 2000
- Country
- ISPR United States
- PACB United States
- Employees
- ISPR N/A
- PACB N/A
- Industry
- ISPR Medicinal Chemicals and Botanical Products
- PACB Biotechnology: Laboratory Analytical Instruments
- Sector
- ISPR Health Care
- PACB Industrials
- Exchange
- ISPR Nasdaq
- PACB Nasdaq
- Market Cap
- ISPR 427.6M
- PACB 452.1M
- IPO Year
- ISPR 2023
- PACB 2010
- Fundamental
- Price
- ISPR $6.25
- PACB $1.72
- Analyst Decision
- ISPR Strong Buy
- PACB Buy
- Analyst Count
- ISPR 1
- PACB 15
- Target Price
- ISPR $12.50
- PACB $3.79
- AVG Volume (30 Days)
- ISPR 187.5K
- PACB 8.3M
- Earning Date
- ISPR 11-11-2024
- PACB 10-28-2024
- Dividend Yield
- ISPR N/A
- PACB N/A
- EPS Growth
- ISPR N/A
- PACB N/A
- EPS
- ISPR N/A
- PACB N/A
- Revenue
- ISPR $151,908,691.00
- PACB $188,871,000.00
- Revenue This Year
- ISPR $44.59
- PACB N/A
- Revenue Next Year
- ISPR N/A
- PACB $28.09
- P/E Ratio
- ISPR N/A
- PACB N/A
- Revenue Growth
- ISPR 31.40
- PACB 29.24
- 52 Week Low
- ISPR $5.01
- PACB $1.16
- 52 Week High
- ISPR $19.78
- PACB $10.65
- Technical
- Relative Strength Index (RSI)
- ISPR 39.80
- PACB 51.79
- Support Level
- ISPR $6.21
- PACB $1.56
- Resistance Level
- ISPR $6.50
- PACB $1.83
- Average True Range (ATR)
- ISPR 0.48
- PACB 0.14
- MACD
- ISPR -0.06
- PACB -0.02
- Stochastic Oscillator
- ISPR 24.51
- PACB 27.59
About ISPR Ispire Technology Inc.
Ispire Technology Inc is engaged in the research and development, design, commercialization, sales, marketing and distribution of branded e-cigarettes and cannabis vaping products.
About PACB Pacific Biosciences of California Inc.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.